Levi & Korsinsky Invites Regeneron Investors to Join Class Action Lawsuit by March 10, 2025
On February 7, 2025, Levi & Korsinsky, LLP publicly announced the initiation of a class action lawsuit targeting Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This lawsuit primarily addresses concerns regarding alleged securities fraud that occurred between November 2, 2023, and October 30, 2024. Investors affected by these circumstances are encouraged to join the legal proceedings by March 10, 2025.
The lawsuit is specifically designed to recuperate losses incurred by investors due to misleading statements made by Regeneron. It accuses the company of concealing crucial details related to its pricing strategies and business operations, particularly concerning its leading product, Eylea. Here are the key allegations:
1. Credit Card Payment Concealment: Regeneron allegedly paid distributors credit card fees on the condition they did not impose higher charges on Eylea customers using credit cards.
2. Price Subsidies: These payments effectively subsidized the prices customers paid when purchasing Eylea through credit cards.
3. Lowered Selling Price: As a result of these actions, Regeneron reportedly lowered Eylea's selling prices, which could mislead investors regarding actual sales figures.
4. Competitive Advantage: The company’s price concessions allowed it to gain a competitive edge in the retina practices market sensitive to pricing dynamics.
5. Inflated Sales Reports: Regeneron is accused of misleadingly reporting inflated sales figures for Eylea due to its undisclosed credit card fee arrangements.
6. Non-Compliance with Regulations: The lawsuit suggests that these actions constituted violations of the False Claims Act, as Regeneron failed to accurately report pricing strategies to federal agencies.
In essence, the complaint claims that the information disclosed, or rather concealed, by Regeneron materially misled both investors and the public about the Company's financial health and projected success.
Investors who have experienced financial losses stemming from their investment in Regeneron during the specified timeframe are encouraged to reach out to Levi & Korsinsky. The deadline to formally join the lawsuit is March 10, 2025. This participation does not necessitate serving as a lead plaintiff, allowing greater flexibility for those interested.
It is important to note that class members may be eligible for compensation without any fees or costs. Levi & Korsinsky emphasizes that there is no financial burden required to be part of the case, further incentivizing investors to step forward.
Levi & Korsinsky is a well-established name in securities litigation, having secured substantial sums for investors over the past two decades. With an experienced team of over 70 professionals, the firm has secured a reputation for effectively representing investors and achieving justice in complex legal matters. The firm has consistently ranked among the top securities litigation firms in the United States, according to ISS Securities Class Action Services.
Investors wishing to join the lawsuit can contact Joseph E. Levi at (212) 363-7500 or via email at email protected]. Further details are also available through their website, [levikorsinsky.com.
With increasing scrutiny on corporate transparency and accountability, this legal action against Regeneron could serve as a pivotal moment for investors seeking reparations for their losses.
Overview of the Lawsuit
The lawsuit is specifically designed to recuperate losses incurred by investors due to misleading statements made by Regeneron. It accuses the company of concealing crucial details related to its pricing strategies and business operations, particularly concerning its leading product, Eylea. Here are the key allegations:
1. Credit Card Payment Concealment: Regeneron allegedly paid distributors credit card fees on the condition they did not impose higher charges on Eylea customers using credit cards.
2. Price Subsidies: These payments effectively subsidized the prices customers paid when purchasing Eylea through credit cards.
3. Lowered Selling Price: As a result of these actions, Regeneron reportedly lowered Eylea's selling prices, which could mislead investors regarding actual sales figures.
4. Competitive Advantage: The company’s price concessions allowed it to gain a competitive edge in the retina practices market sensitive to pricing dynamics.
5. Inflated Sales Reports: Regeneron is accused of misleadingly reporting inflated sales figures for Eylea due to its undisclosed credit card fee arrangements.
6. Non-Compliance with Regulations: The lawsuit suggests that these actions constituted violations of the False Claims Act, as Regeneron failed to accurately report pricing strategies to federal agencies.
In essence, the complaint claims that the information disclosed, or rather concealed, by Regeneron materially misled both investors and the public about the Company's financial health and projected success.
Next Steps for Investors
Investors who have experienced financial losses stemming from their investment in Regeneron during the specified timeframe are encouraged to reach out to Levi & Korsinsky. The deadline to formally join the lawsuit is March 10, 2025. This participation does not necessitate serving as a lead plaintiff, allowing greater flexibility for those interested.
No Financial Obligation for Participation
It is important to note that class members may be eligible for compensation without any fees or costs. Levi & Korsinsky emphasizes that there is no financial burden required to be part of the case, further incentivizing investors to step forward.
Why Choose Levi & Korsinsky?
Levi & Korsinsky is a well-established name in securities litigation, having secured substantial sums for investors over the past two decades. With an experienced team of over 70 professionals, the firm has secured a reputation for effectively representing investors and achieving justice in complex legal matters. The firm has consistently ranked among the top securities litigation firms in the United States, according to ISS Securities Class Action Services.
Contact Information
Investors wishing to join the lawsuit can contact Joseph E. Levi at (212) 363-7500 or via email at email protected]. Further details are also available through their website, [levikorsinsky.com.
With increasing scrutiny on corporate transparency and accountability, this legal action against Regeneron could serve as a pivotal moment for investors seeking reparations for their losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.